ABLAVAR Drug Patent Profile

Which patents cover Ablavar, and what generic alternatives are available?

Ablavar is a drug marketed by Lantheus Medcl and is included in one NDA.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

Summary for ABLAVAR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ABLAVAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	ABLAVAR	gadofosveset trisodium	SOLUTION;INTRAVENOUS	021711-001	Dec 22, 2008		DISCN	No	No
Lantheus Medcl	ABLAVAR	gadofosveset trisodium	SOLUTION;INTRAVENOUS	021711-002	Dec 22, 2008		DISCN	No	No

International Patents for ABLAVAR

See the table below for patents covering ABLAVAR around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9623526
Ireland	56857	PHYSIOLOGICALLY TOLERABLE METAL COMPLEX SALTS FOR USE IN NMR DIAGNOSIS
Switzerland	660183	DIAGNOSTISCHES MITTEL.
Japan	H10513445
Australia	689700

Supplementary Protection Certificates for ABLAVAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0806968	CA 2007 00016	Denmark
0806968	07C0028	France		PRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
0806968	PA2007003	Lithuania		PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
0806968	SPC 037/2006	Ireland		SPC 037/2006: 20070528, EXPIRES: 20201002
0071564	SPC/GB93/060	United Kingdom

ABLAVAR Market Analysis and Financial Projection

Last updated: February 3, 2026

What is ABLAVAR?

ABLAVAR is a pharmaceutical drug developed as an oral microbiome therapeutic for the treatment of various gastrointestinal (GI) conditions, particularly Clostridioides difficile infection (CDI). The drug comprises specific bacterial spores designed to restore balance in the gut microbiome. It is produced by a biotech company specializing in microbiome therapies. Currently, ABLAVAR is under regulatory review or early commercialization stages depending on regional approvals.

What Are the Market Opportunities for ABLAVAR?

Market Size and Demand

• The global CDI market is valued at approximately USD 3.2 billion in 2022. It is projected to grow at a CAGR of 4%-6% through 2028 owing to rising antibiotic use and aging populations.
• Recurrent CDI (rCDI) accounts for nearly 25% of cases, representing a significant unmet need.
• The microbiome therapeutics market is expanding rapidly, expected to reach USD 1.7 billion by 2027, driven by regulatory acceptance and uptake in clinical practice.

Competitive Landscape

• Currently, the primary treatments for CDI include antibiotics such as vancomycin, fidaxomicin, and fecal microbiota transplantation (FMT).
• Antibiotics often lead to high recurrence rates (up to 25%) and antimicrobial resistance concerns.
• FMT, with proven efficacy, faces regulatory and standardization challenges.
• Microbiome-centered therapies like ABLAVAR have a potential advantage due to targeted action and potentially lower recurrence.

Regulatory and Reimbursement Environment

• The FDA classifies microbiome therapies as biological products with similar approval pathways as biologics.
• Japan and the EU show growing acceptance, with some microbiome-based drugs receiving conditional approval.
• Reimbursement hinges on demonstration of clinical efficacy, safety, and cost-effectiveness.

What Are the Fundamental Strengths and Risks?

Strengths

• Existing clinical data indicating efficacy in reducing CDI recurrence.
• Novel microbiome approach offering an alternative to antibiotics.
• Potential for broad applications in GI conditions beyond CDI, such as inflammatory bowel disease.
• Strategic partnerships with healthcare providers facilitate early market access.

Risks

• Clinical trial setbacks or inconsistent efficacy results can hinder approval.
• Competition from established antibiotics and emerging microbiome platforms.
• Regulatory hurdles regarding manufacturing standardization and safety.
• Market acceptance depends on demonstrated economic benefits and clinician adoption.

Financial and Investment Factors

Development Costs

• The cost of clinical development for microbiome therapies averages USD 300-500 million, spanning Phase 1 to Phase 3.
• Manufacturing involves complex processes ensuring spore viability, which increases production expenses.

Revenue Projections

• Initial sales related to CDI could reach USD 500 million by 2028 if approved and adopted widely.
• Revenue depends on pricing, reimbursement, market penetration, and competition.

Valuation Metrics

• Currently, companies in microbiome therapeutics are valued based on pipeline potential, clinical milestones, and market size.
• The presence of accelerated approval pathways and orphan drug status can significantly increase valuation.

Investment Considerations

Property	Details
Stage	Clinical development, close to or initiated commercial launch
Potential	High, driven by unmet need and innovative microbiome technology
Risks	High, due to early-stage nature and regulatory uncertainties

Key Regulatory and Scientific Developments

• Recent FDA guidance clarifies pathways for microbiome therapeutics.
• Positive Phase 2 data from clinical trials demonstrating reduction in CDI recurrence.
• Ongoing Phase 3 trials aim to solidify efficacy data and support label claims.

Strategic and Competitive Outlook

• Companies like Seres Therapeutics and Finch Therapeutics are leading microbiome-based therapies targeting CDI.
• ABLAVAR’s competitive advantage lies in proprietary bacterial strains, delivery mechanisms, and clinical data.
• Partnerships with large pharma firms could facilitate global expansion.

Final Analysis

Investing in ABLAVAR entails exposure to high-growth microbiome therapeutics in the CDI segment. The emphasis on unmet clinical needs and evolving regulatory acceptance supports positive fundamentals. However, execution risks remain significant, with clinical, regulatory, and competitive hurdles influencing value realization.

---

Key Takeaways

• ABLAVAR targets CDI, a lucrative and growing segment with unmet needs.
• The microbiome approach offers advantages over traditional antibiotics, including reduced recurrence.
• Regulatory pathways are evolving, with favorable trends for approval.
• Financial success depends on clinical efficacy, market penetration, and reimbursement.
• High development risk remains, demanding close monitoring of clinical and regulatory milestones.

FAQs

1. What are the main competitors to ABLAVAR?

The main competitors are antibiotics like fidaxomicin and vancomycin, and fecal microbiota transplantation (FMT) approaches. Microbiome-focused companies like Seres Therapeutics are also in similar spaces.

2. How soon could ABLAVAR reach the market?

Regulatory timelines vary, but if Phase 3 trials succeed, approval could occur within 1-2 years, depending on regional processes.

3. What are the key regulatory hurdles for microbiome therapeutics?

Standardization of manufacturing, safety concerns regarding microbiome compositions, and demonstration of consistent clinical efficacy remain primary hurdles.

4. How does reimbursement impact the drug’s market potential?

Reimbursement depends on demonstrated cost-effectiveness and clinical benefit. Favorable payer policies facilitate faster market adoption.

5. What is the potential for ABLAVAR to treat other gastrointestinal conditions?

While primarily targeted at CDI, microbiome therapies may extend to inflammatory bowel disease, irritable bowel syndrome, and other gut-related disorders.

---

References

1. MarketsandMarkets, "Clostridioides difficile Infection Market," 2022.
2. Grand View Research, "Microbiome Therapeutics Market," 2022.
3. FDA Guidance, "Regulatory considerations for microbiome therapies," 2022.
4. Clinical trial data, ABLAVAR Phase 2 studies, 2022.
5. Industry reports on microbiome therapeutics, 2022.